Indivior Pharmaceuticals Reports Q4 2025 Earnings Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy INDV?
Source: seekingalpha
- Financial Performance Growth: Indivior achieved total net revenue of $1.24 billion in 2025, a 4% year-over-year increase, with SUBLOCADE net revenue reaching $856 million, reflecting a 13% growth from 2024, indicating strong market performance and sustained growth potential.
- Share Repurchase Program: The company announced a new $400 million share repurchase program aimed at enhancing shareholder value while completing a $295 million DOJ obligation payment in 2025, further optimizing its financial structure.
- Optimistic Future Outlook: Indivior reaffirmed its 2026 total net revenue guidance in the range of $1.125 billion to $1.195 billion, with projected SUBLOCADE net revenue growth of 8%, reflecting confidence in future market demand.
- Operational Efficiency Improvement: Adjusted EBITDA for Q4 increased by 91% to $142 million, with full-year EBITDA rising 20% to $428 million, showcasing significant improvements in cost control and operational efficiency.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INDV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INDV
Wall Street analysts forecast INDV stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 31.980
Low
36.00
Averages
43.75
High
50.00
Current: 31.980
Low
36.00
Averages
43.75
High
50.00
About INDV
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Indivior Pharmaceuticals Reports Q4 2025 Earnings Highlights
- Financial Performance Growth: Indivior achieved total net revenue of $1.24 billion in 2025, a 4% year-over-year increase, with SUBLOCADE net revenue reaching $856 million, reflecting a 13% growth from 2024, indicating strong market performance and sustained growth potential.
- Share Repurchase Program: The company announced a new $400 million share repurchase program aimed at enhancing shareholder value while completing a $295 million DOJ obligation payment in 2025, further optimizing its financial structure.
- Optimistic Future Outlook: Indivior reaffirmed its 2026 total net revenue guidance in the range of $1.125 billion to $1.195 billion, with projected SUBLOCADE net revenue growth of 8%, reflecting confidence in future market demand.
- Operational Efficiency Improvement: Adjusted EBITDA for Q4 increased by 91% to $142 million, with full-year EBITDA rising 20% to $428 million, showcasing significant improvements in cost control and operational efficiency.
See More
Indivior Q4 Earnings Exceed Expectations
- Strong Earnings Report: Indivior reported a Q4 non-GAAP EPS of $0.82, beating expectations by $0.15, which demonstrates robust profitability growth and enhances investor confidence in the company's performance.
- Significant Revenue Growth: The company achieved Q4 revenue of $358 million, representing a 20.1% year-over-year increase and exceeding market expectations by $52.38 million, indicating strong demand and sales performance.
- 2026 Financial Guidance: Indivior projects net revenue for 2026 to be between $1.125 billion and $1.195 billion, with SUBLOCADE net revenue expected to range from $905 million to $945 million, reflecting confidence in future growth and strategic planning.
- Cost Control Measures: The company anticipates non-GAAP operating expenses to be between $430 million and $450 million, with adjusted EBITDA projected at $535 million to $575 million, showcasing ongoing efforts in cost management and profitability enhancement.
See More
Kevin Mahn Advises Investors to Focus on Long-Term Growth Amid Market Volatility
- Market Volatility Impact: Kevin Mahn highlighted that in 2025, markets initially fell nearly 15% due to tariff fears, but those who remained invested saw a 39% rebound by year-end, underscoring the risks of reacting to short-term headlines.
- Identifying Investment Opportunities: Mahn advised investors to focus on long-term growth, particularly the AI boom, with trillions expected in infrastructure investments by 2030, emphasizing the potential of companies supporting this growth, such as data center cooling and power providers.
- Stability and Yield: He mentioned Comfort Systems USA Inc., recently added to the S&P 500, and Duke Energy Corp., trading at 17X forward earnings with a 3.7% dividend yield, as solid choices for stability in turbulent markets.
- Sector Outlook: Mahn also pointed out promising sectors like aerospace and defense, driven by rising global military budgets, and small-cap biotech, benefiting from patent cliffs and M&A activity, recommending companies like L3 Harris and Indivior as investment targets.
See More
Healthcare Sector Outperforms S&P 500 with 12.52% Gain and 3.20 Health Score
- Sector Performance: The S&P 500 healthcare sector achieved a 12.52% gain in 2025, lagging behind the broader S&P 500 index's 16.39% increase, indicating relative strength within the healthcare industry.
- Health Score Analysis: Seeking Alpha's Quant Ratings assign an average health score of 3.20 out of 5 to the healthcare sector, based on 261 stocks with market capitalizations above $2 billion, reflecting a generally healthy outlook for the sector.
- Stock Rating Distribution: Among the 261 stocks, 37 are rated Buy or higher, 213 are Neutral, and 11 are Strong Sell, showcasing varied market perceptions and investment opportunities within the healthcare sector.
- Top Stock Ratings: Ahead of the upcoming earnings season, stocks like Grail (GRAL) and Indivior PLC (INDV) received strong buy ratings of 4.97 and 4.95, respectively, indicating strong investor confidence in these companies.
See More
Indivior Stock Performance Review: Short-Term Decline vs. Long-Term Gains
- Short-Term Fluctuations: Indivior's recent stock price has declined by 0.20% in one day and 0.81% over the past week, indicating a reassessment by investors of the growth prospects and risks associated with the current share price of $35.44, which may impact short-term investor confidence.
- Long-Term Returns: Despite the recent downturn, Indivior has achieved a 49.03% return over the past 90 days and a total shareholder return of 199.07% over the past year, suggesting strong long-term investment value that continues to attract attention.
- Valuation Analysis: With a P/E ratio of 35.7x, Indivior is slightly below the peer average of 36.1x but significantly above the broader pharmaceuticals industry at 19.7x, indicating a premium attached to its earnings profile that could influence future investment decisions.
- Cash Flow Model: While the P/E ratio suggests Indivior is relatively expensive, the SWS discounted cash flow model estimates a fair value of $108.17, implying that the current stock price is materially undervalued, prompting investors to weigh different valuation signals.
See More
Stonepine Capital Reduces Indivior Stake by 250,000 Shares, Valuation Drops by $2.75 Million
- Reduction Action: Stonepine Capital reduced its Indivior stake by 250,000 shares in Q3, leading to a valuation drop of approximately $2.75 million, indicating a cautious outlook on the company's future performance.
- Position Change: As of September 30, Stonepine held 100,000 shares of Indivior valued at $2.41 million, with its stake percentage decreasing from 5.06% to 1.96%, reflecting diminished confidence in the stock.
- Performance Metrics: Indivior reported $314 million in revenue for Q3, with SUBLOCADE sales increasing 15% year-over-year to $219 million, driving a 14% rise in adjusted EBITDA to $120 million, showcasing improved operational momentum.
- Future Guidance: Indivior's management raised its full-year 2025 revenue guidance sharply to $1.18 billion to $1.22 billion and plans to save at least $150 million in annual operating expenses starting next year, demonstrating a strategic commitment to cost discipline and sustained growth.
See More
Indivior Pharmaceuticals Reports Q4 2025 Earnings Highlights
- Financial Performance Growth: Indivior achieved total net revenue of $1.24 billion in 2025, a 4% year-over-year increase, with SUBLOCADE net revenue reaching $856 million, reflecting a 13% growth from 2024, indicating strong market performance and sustained growth potential.
- Share Repurchase Program: The company announced a new $400 million share repurchase program aimed at enhancing shareholder value while completing a $295 million DOJ obligation payment in 2025, further optimizing its financial structure.
- Optimistic Future Outlook: Indivior reaffirmed its 2026 total net revenue guidance in the range of $1.125 billion to $1.195 billion, with projected SUBLOCADE net revenue growth of 8%, reflecting confidence in future market demand.
- Operational Efficiency Improvement: Adjusted EBITDA for Q4 increased by 91% to $142 million, with full-year EBITDA rising 20% to $428 million, showcasing significant improvements in cost control and operational efficiency.
See More
Indivior Q4 Earnings Exceed Expectations
- Strong Earnings Report: Indivior reported a Q4 non-GAAP EPS of $0.82, beating expectations by $0.15, which demonstrates robust profitability growth and enhances investor confidence in the company's performance.
- Significant Revenue Growth: The company achieved Q4 revenue of $358 million, representing a 20.1% year-over-year increase and exceeding market expectations by $52.38 million, indicating strong demand and sales performance.
- 2026 Financial Guidance: Indivior projects net revenue for 2026 to be between $1.125 billion and $1.195 billion, with SUBLOCADE net revenue expected to range from $905 million to $945 million, reflecting confidence in future growth and strategic planning.
- Cost Control Measures: The company anticipates non-GAAP operating expenses to be between $430 million and $450 million, with adjusted EBITDA projected at $535 million to $575 million, showcasing ongoing efforts in cost management and profitability enhancement.
See More
Kevin Mahn Advises Investors to Focus on Long-Term Growth Amid Market Volatility
- Market Volatility Impact: Kevin Mahn highlighted that in 2025, markets initially fell nearly 15% due to tariff fears, but those who remained invested saw a 39% rebound by year-end, underscoring the risks of reacting to short-term headlines.
- Identifying Investment Opportunities: Mahn advised investors to focus on long-term growth, particularly the AI boom, with trillions expected in infrastructure investments by 2030, emphasizing the potential of companies supporting this growth, such as data center cooling and power providers.
- Stability and Yield: He mentioned Comfort Systems USA Inc., recently added to the S&P 500, and Duke Energy Corp., trading at 17X forward earnings with a 3.7% dividend yield, as solid choices for stability in turbulent markets.
- Sector Outlook: Mahn also pointed out promising sectors like aerospace and defense, driven by rising global military budgets, and small-cap biotech, benefiting from patent cliffs and M&A activity, recommending companies like L3 Harris and Indivior as investment targets.
See More
Healthcare Sector Outperforms S&P 500 with 12.52% Gain and 3.20 Health Score
- Sector Performance: The S&P 500 healthcare sector achieved a 12.52% gain in 2025, lagging behind the broader S&P 500 index's 16.39% increase, indicating relative strength within the healthcare industry.
- Health Score Analysis: Seeking Alpha's Quant Ratings assign an average health score of 3.20 out of 5 to the healthcare sector, based on 261 stocks with market capitalizations above $2 billion, reflecting a generally healthy outlook for the sector.
- Stock Rating Distribution: Among the 261 stocks, 37 are rated Buy or higher, 213 are Neutral, and 11 are Strong Sell, showcasing varied market perceptions and investment opportunities within the healthcare sector.
- Top Stock Ratings: Ahead of the upcoming earnings season, stocks like Grail (GRAL) and Indivior PLC (INDV) received strong buy ratings of 4.97 and 4.95, respectively, indicating strong investor confidence in these companies.
See More
Indivior Stock Performance Review: Short-Term Decline vs. Long-Term Gains
- Short-Term Fluctuations: Indivior's recent stock price has declined by 0.20% in one day and 0.81% over the past week, indicating a reassessment by investors of the growth prospects and risks associated with the current share price of $35.44, which may impact short-term investor confidence.
- Long-Term Returns: Despite the recent downturn, Indivior has achieved a 49.03% return over the past 90 days and a total shareholder return of 199.07% over the past year, suggesting strong long-term investment value that continues to attract attention.
- Valuation Analysis: With a P/E ratio of 35.7x, Indivior is slightly below the peer average of 36.1x but significantly above the broader pharmaceuticals industry at 19.7x, indicating a premium attached to its earnings profile that could influence future investment decisions.
- Cash Flow Model: While the P/E ratio suggests Indivior is relatively expensive, the SWS discounted cash flow model estimates a fair value of $108.17, implying that the current stock price is materially undervalued, prompting investors to weigh different valuation signals.
See More
Stonepine Capital Reduces Indivior Stake by 250,000 Shares, Valuation Drops by $2.75 Million
- Reduction Action: Stonepine Capital reduced its Indivior stake by 250,000 shares in Q3, leading to a valuation drop of approximately $2.75 million, indicating a cautious outlook on the company's future performance.
- Position Change: As of September 30, Stonepine held 100,000 shares of Indivior valued at $2.41 million, with its stake percentage decreasing from 5.06% to 1.96%, reflecting diminished confidence in the stock.
- Performance Metrics: Indivior reported $314 million in revenue for Q3, with SUBLOCADE sales increasing 15% year-over-year to $219 million, driving a 14% rise in adjusted EBITDA to $120 million, showcasing improved operational momentum.
- Future Guidance: Indivior's management raised its full-year 2025 revenue guidance sharply to $1.18 billion to $1.22 billion and plans to save at least $150 million in annual operating expenses starting next year, demonstrating a strategic commitment to cost discipline and sustained growth.
See More
